Skip to main content
. 2018 Aug 22;10(2):408–417. doi: 10.1111/jdi.12900

Table 1.

Baseline demographic and clinical characteristics of the patients

Total Nausea and vomiting (−) Nausea and vomiting (+) P‐value
n (Liraglutide/lixisenatide) 130 (83 / 47) 85 (59 / 26) 45 (24 / 21)
Sex (% male) 45.4 52.9 31.1 0.026
Age (years) 56.8 ± 13.3 56.3 ± 13.7 57.8 ± 12.6 0.529
Duration of diabetes (years) 12.2 ± 9.6 11.5 ± 9.3 13.4 ± 10.1 0.309
BMI (kg/m2) 27.5 (24.6–32.2) 27.8 (25.4–32.3) 25.9 (24.1–31.1) 0.292
HbA1c (%) 9.0 ± 1.7 9.0 ± 1.7 8.9 ± 1.8 0.673
SBP (mmHg) 133.9 ± 18.8 133.8 ± 17.4 134.2 ± 21.2 0.899
DBP (mmHg) 75.4 ± 13.5 75.2 ± 13.5 75.8 ± 13.6 0.796
AST (U/L) 22 (17–31) 21 (17–29) 23 (17–32) 0.448
ALT (U/L) 24 (17–39) 24 (17–39) 24 (20–37) 0.609
eGFR (mL/min/1.73 m2) 75.1 ± 20.5 77.0 ± 19.5 71.5 ± 22 0.146
CrCl (mL/min) 110.7 ± 54.0 116.2 ± 55.6 100.3 ± 49.8 0.140
HDL cholesterol (mmol/L) 50.8 ± 11.1 50.1 ± 10.8 52.1 ± 11.7 0.350
LDL cholesterol (mmol/L) 115.2 ± 31.6 118.4 ± 31.5 109.1 ± 31.1 0.111
TG (mmol/L) 145 (99–227) 146 (99–228) 144 (102–214) 0.619
Diabetes complications (%)
Retinopathy 37.7 29.4 53.3 0.013
Nephropathy 41.5 37.6 48.9 0.160
Previous antidiabetic treatment (%)
Diet only 14.6 17.6 8.9 0.204
Sulfonylureas 39.2 40.0 37.8 0.852
Metformin 41.5 41.2 42.2 1
Glinides 6.2 5.9 6.7 1
α‐Glycosidase inhibitors 15.4 14.1 17.8 0.615
Pioglitazone 8.5 10.6 4.4 0.328
DPP‐4 inhibitors 27.7 24.7 33.3 0.310
Insulin 29.2 30.6 26.7 0.690
Treatment with PPIs or H2RAs (%) 14.6 10.6 22.2 0.115

Data are expressed as the mean ± standard deviation, median and interquartile range or numbers and percentages. The statistical significance was estimated using Student's t‐test or the Mann–Whitney U‐test for continuous variables, and Fisher's exact test for categorical variables. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CrCl, creatinine clearance; DBP, diastolic blood pressure; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; H2RAs, histamine‐2 receptor antagonists; LDL, low‐density lipoprotein; PPIs, proton pump inhibitors; SBP, systolic blood pressure; TG, triglyceride.